Cell Symposia: The Biology of Neuropsychiatric Disorders
May 15–17, 2022 | Sitges, Spain
ABSTRACT SUBMISSION DEADLINE JANUARY 28, 2022
SUBMIT YOUR ABSTRACTS HERE >
Treating psychiatric disorders is one of the key challenges of our time. Recent advances in technology and research have led to new insights in the fields of neuropsychiatry from genetics to behavior, and from basic animal to human clinical and cognitive studies, that have direct consequences for our understanding and treatment of disease.
The meeting will cover both basic neuroscientific and genetic approaches as well as translational topics in neuropsychiatry, bringing together thought leaders within these fields and providing a forum for sharing and disseminating the latest advances and provide a common ground for cross-disciplinary discussion and collaboration between the fields to understand the pathogenesis of these disorders and improve diagnosis and therapeutics.
Our topics will include:
- Genetic and molecular disease mechanisms
- Disease modeling
- Neural circuits
- Neuroscientific tools and translational implications
- Cognitive neuropsychiatry
Symposium topics and key questions that they will address that bridge the interest of both basic neuroscientists to clinicians:
Genetic and molecular mechanisms
What can genetics tell us about the likely etiology of these disorders, their diagnosis, prognosis, and options for treatment and potential prevention?
Are the behavioral manifestations of these disorders recapitulated in models that can inform treatment and understanding of neurological underpinnings of disease? Are there hallmarks of neural circuitry that can help stratify the disorders?
What are the current and future models for psychiatric disorders: Can complex diseases be modeled (syndrome/symptom approach), and how will these models shape our understanding of its etiology and their translational potential to design novel and effective treatment options for patients?
Treatment mechanisms and application
How are current avenues for treatment faring, what can they tell us about what more needs to be done to improve treatment and understanding of these complex disorders, and is prevention possible?
Human cognition and clinical studies
Working directly with patients, what do we know about the range of symptoms, co-morbidity, timing of diagnosis, and efficacy of therapies based on patient studies? What can we learn from normal cognitive development and how it becomes pathological?
- Thomas Südhof, USA
- Claudia Bagni, Switzerland
- Ed Bullmore, UK
- Pico Caroni, Switzerland
- Karl Deisseroth, USA
- Ray Dolan, UCL, UK
- Kafui Dzirasa, USA
- Damien Fair, USA
- Guoping Feng, USA
- Jonathan Flint, USA
- Daniel Geschwind, USA
- Hailan Hu, China
- Yasmin Hurd, USA
- Christian Luscher, Switzerland
- Sergiu Pasca, USA
- Danielle Posthuma, Netherlands
- Angela Roberts, UK
- Bryan Roth, USA
- Alcino Silva, USA
March 2–4, 2020
San Francisco, CA, USA
November 17 – 19, 2019
Seattle, WA, USA
November 17 – 19, 2019
October 20 — 22, 2019
Chicago, IL, USA